It represents an allosteric inhibitor of IGF2BP1 in melanoma and ovarian cancer cell lines and also reduces mRNA levels of other cancer-related IGF2BP1 targets like eukaryotic elongation factor 2 (eEF2), cell division cycle 34 (CDC34), calmodulin 1 (CALM1), beta-transducin repeat containing E3 ubiquitin protein ligase 1 (β-TRCP1), and collagen type V alpha 1 chain (COL5A1). This evidence concerns the gene CALM1 and ovarian carcinoma.